Determinant spreading and tumor responses after peptide-based cancer immunotherapy.
Modern immunological assays are very sensitive for detection of antigen-specific T cells. These assays are used to detect increased levels of T cells after peptide-based immunotherapy for cancer in an attempt to describe surrogate endpoints correlated with anti-tumor activity. Recent reports demonstrate that determinant spreading develops in a high frequency of subjects with tumor regression responses after this type of immunotherapy and could be valuable for trial monitoring and the design of more effective vaccines.
Ribas
Antoni
A
Department of Medicine, 54-140 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA. aribas@mednet.ucla.edu
Timmerman
John M
JM
Butterfield
Lisa H
LH
Economou
James S
JS
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology; D000939:Epitopes; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D010455:Peptides / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D019496:Cancer Vaccines; D000939:Epitopes; D010455:Peptides